ZYNDIKATE® offers a palette of drug delivery systems supporting various routes of administration (oral, sublingual, intra-nasal, transdermal etc.). These formulations are designed to accommodate drug molecules within a predefined range of physicochemical property descriptors compatible with most ligands from the ZEEK™ phase.

ZYNDIKATE® enables the early introduction of a delivery system that resembles the intended commercial formulation. This reduces the burden of manufacturing, the so-called CMC-burden, while also eliminating the need for reformulation of the investigational medicinal product as the drug candidate progresses through the clinical phases.

This eliminates the need for often unpredictable bioequivalence testing, significantly derisking the pipeline program as a whole. Decreasing the CMC burden is a central aspect of the Tetra Pharm Technologies way of doing science. It is also an essential part of our strategy to reduce the cost of our products. 

Key benefits of ZYNDIKATE®

• Increased Bioavailability

• Fast Onset

• Consistent Absorption Rate

• Multiple Dosage Forms

• Extended Stability (Expiry)

• Lower Toxicity Risk

• Competitive Edge